Focal Segmental Glomerulosclerosis Drugs Market Trends 2025–2029: Regional Outlook and Sizing Analysis
Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Much Will The Focal Segmental Glomerulosclerosis Drugs Market Be Worth By 2029?
The market for drugs treating focal segmental glomerulosclerosis has witnessed significant growth in the past few years. The market size, which stands at $15.77 billion in 2024, is expected to reach $17 billion by 2025, growing at a compound annual growth rate (CAGR) of 7.8%. The factors contributing to the growth observed in the past include an increased prevalence of the disease, escalating demand for innovative treatments, rising interest from the pharmaceutical sector, and expanded government support.
The market for drugs used to treat focal segmental glomerulosclerosis is forecasted to experience substantial growth in the coming years. It is anticipated to reach a valuation of “$24.79 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.9%. The expansion during the forecasted period can be credited to factors such as increased expenditure on research and development, augmentation in healthcare spending, rising awareness and improved diagnostics, a growing elderly population, government initiatives and financial support. Key trends expected in the forecast period encompass advancements in technology for drug discovery and development, a growing pipeline of clinical trials, improved reimbursements for treatments using focal segmental glomerulosclerosis drugs, and the growth of corporate research facilities.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp
Which Industry Forces Are Driving The Focal Segmental Glomerulosclerosis Drugs Market Forward?
The escalating instances of kidney infections are anticipated to drive the expansion of the market for focal segmental glomerulosclerosis (FSGS) drugs. Kidney infection, also known as pyelonephritis, is a serious form of urinary tract infection that impacts one or both kidneys. FSGS drugs are employed to combat kidney illnesses and provide substantial benefits in managing the condition. These advantages include improving kidney performance by decreasing proteinuria, slowing down kidney deterioration, and enhancing the quality of life of kidney disease patients. For instance, as per the US Department of Health and Human Services’ Centers for Disease Control and Prevention, around 15% or 37 million people in the US suffered from kidney disease as of July 2022. The disease was prevalent in 12% of those aged 45-64 years and 6% of people between the ages of 18 and 44, in 2021. Consequently, the increasing frequency of kidney infections propels the growth of the focal segmental glomerulosclerosis (FSGS) market.
Which Segmentation Factors Are Critical In The Focal Segmental Glomerulosclerosis Drugs Market Analysis?
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
What Are The Dominant Trends Currently Seen In The Focal Segmental Glomerulosclerosis Drugs Market?
Major corporations engaged in the focal segmental glomerulosclerosis (FSGS) market, are intensifying their efforts on product innovation and advancement to supply reliable goods to customers and bolster their market standing. For instance, Travere Therapeutics, an American biopharmaceutical enterprise, launched FILSPARI in February 2023 for FSGS. This launch was sanctioned by the US-based federal body, the Food and Drug Administration (FDA). This orally administered medicine is aimed at treating IgA nephropathy (IgAN). It is the premier and sole non-immunosuppressive treatment aimed at reducing proteinuria in IgAN, a rarely occurring kidney disease. As an additional point, FILSPARI has been granted the status of orphan drug in both the United States and Europe, for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).
Who Are The Dominant Players In The Focal Segmental Glomerulosclerosis Drugs Market Today?
Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Focal Segmental Glomerulosclerosis Drugs Market?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12866&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
